Loading clinical trials...
Loading clinical trials...
The investigators recently identified promiscuous HLA-DR-derived epitopes from the human telomerase reverse transcriptase (TERT) called universal cancer peptides (UCP), to study tumor-specific CD4+ T ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
NCT07445984 · Chronic Leukemia, Acute Leukemia, and more
NCT06297161 · Chronic Leukemia Myelogenous
NCT04965649 · Leukemia, Myelogenous Leukemia, and more
NCT01598025 · Acute Leukemia, Chronic Leukemia, and more
NCT02451592 · Acute Leukemia, Chronic Leukemia, and more
Centre Hospitalier Régional Universitaire de Besançon
Besançon
CHU de Dijon
Dijon
CHU de Nice
Nice
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions